Your browser is no longer supported. Please, upgrade your browser.
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-7.03 Insider Own4.10% Shs Outstand77.97M Perf Week-3.29%
Market Cap10.82B Forward P/E- EPS next Y-4.20 Insider Trans-5.33% Shs Float74.71M Perf Month-0.02%
Income-530.30M PEG- EPS next Q-1.76 Inst Own94.90% Short Float12.21% Perf Quarter-13.08%
Sales450.20M P/S24.03 EPS this Y-77.80% Inst Trans-0.12% Short Ratio13.75 Perf Half Y12.78%
Book/sh13.38 P/B10.29 EPS next Y29.90% ROA-22.70% Target Price192.57 Perf Year64.89%
Cash/sh26.24 P/C5.25 EPS next 5Y-0.20% ROE-53.00% 52W Range78.06 - 175.00 Perf YTD6.73%
Dividend- P/FCF46.23 EPS past 5Y-23.40% ROI-47.10% 52W High-21.30% Beta2.10
Dividend %- Quick Ratio6.40 Sales past 5Y108.10% Gross Margin87.90% 52W Low76.44% ATR4.66
Employees743 Current Ratio6.90 Sales Q/Q45.10% Oper. Margin- RSI (14)41.87 Volatility2.76% 3.39%
OptionableYes Debt/Eq0.67 EPS Q/Q48.20% Profit Margin- Rel Volume0.56 Prev Close137.80
ShortableYes LT Debt/Eq0.67 EarningsAug 05 AMC Payout- Avg Volume663.68K Price137.73
Recom1.70 SMA20-2.73% SMA50-3.42% SMA2002.03% Volume372,399 Change-0.05%
Aug-25-20Initiated Raymond James Outperform $200
Aug-20-20Downgrade Credit Suisse Outperform → Neutral $185 → $167
Mar-31-20Initiated Mizuho Buy $183
Nov-01-19Initiated Guggenheim Buy $183
Aug-21-19Reiterated Needham Buy $196 → $170
Jul-09-19Reiterated Morgan Stanley Overweight $165 → $220
Jul-01-19Reiterated RBC Capital Mkts Outperform $188 → $220
Apr-12-19Initiated Evercore ISI Outperform
Mar-11-19Reiterated Credit Suisse Outperform $189 → $207
Oct-12-18Initiated Bernstein Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Sep-26-18Reiterated RBC Capital Mkts Outperform $187 → $200
Sep-14-18Resumed BofA/Merrill Buy $199
Sep-06-18Initiated Credit Suisse Outperform $178
Aug-01-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-21-18Reiterated Robert W. Baird Outperform $120 → $202
Jun-20-18Reiterated Needham Buy $109 → $204
Jun-19-18Reiterated H.C. Wainwright Buy $96 → $267
May-18-18Reiterated Goldman Buy $84 → $127
May-11-18Upgrade Barclays Equal Weight → Overweight $55 → $107
Oct-23-20 12:56PM  
Oct-22-20 07:30AM  
Oct-01-20 04:43PM  
Sep-30-20 06:15PM  
Sep-28-20 05:06PM  
Sep-16-20 10:29AM  
Sep-15-20 08:30AM  
Sep-14-20 08:30AM  
Sep-10-20 04:32PM  
Sep-09-20 05:19PM  
Sep-08-20 11:58PM  
Sep-04-20 11:31AM  
Sep-03-20 04:30PM  
Aug-31-20 06:30PM  
Aug-26-20 10:44PM  
Aug-25-20 04:45PM  
Aug-11-20 10:19AM  
Aug-06-20 10:54AM  
Aug-05-20 06:05PM  
Jul-31-20 06:15PM  
Jul-29-20 12:33PM  
Jul-24-20 01:59PM  
Jul-15-20 08:30AM  
Jul-10-20 08:47PM  
Jul-02-20 08:21AM  
Jun-30-20 06:15PM  
Jun-29-20 10:06AM  
Jun-26-20 08:30AM  
Jun-23-20 04:05PM  
Jun-22-20 08:00AM  
Jun-18-20 08:30AM  
Jun-16-20 12:00PM  
Jun-15-20 04:02PM  
Jun-09-20 10:34AM  
Jun-08-20 04:15PM  
Jun-05-20 04:05PM  
Jun-02-20 08:57PM  
May-29-20 06:28PM  
May-28-20 11:30AM  
May-18-20 11:38AM  
May-15-20 04:15PM  
May-14-20 10:53AM  
May-13-20 02:56PM  
May-12-20 04:30PM  
May-11-20 07:00AM  
May-07-20 11:41AM  
May-06-20 06:15PM  
Apr-30-20 06:52PM  
Apr-29-20 08:30AM  
Apr-28-20 08:30AM  
Apr-15-20 08:34AM  
Apr-14-20 07:29AM  
Apr-08-20 02:19PM  
Mar-31-20 06:06PM  
Mar-27-20 11:31AM  
Mar-24-20 02:20AM  
Mar-11-20 07:57PM  
Feb-28-20 06:20PM  
Feb-27-20 10:47AM  
Feb-26-20 06:15PM  
Feb-19-20 12:31PM  
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; SRP-9003, a limb-girdle muscular dystrophies gene therapy program; and LYS-SAF 302 to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; StrideBio; the United States Army Medical Research Institute of Infectious Diseases; the Department of Defense's lead laboratory; the Dyno Therapeutics, Inc; and Personalis, Inc. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wigzell Hans Lennart RudolfDirectorAug 10Option Exercise34.9210,000349,20023,792Aug 11 08:00 PM
Wigzell Hans Lennart RudolfDirectorAug 10Sale159.0010,0001,590,04413,792Aug 11 08:00 PM
Barry RichardDirectorAug 07Sale158.5030,0004,754,9723,129,140Aug 07 08:00 PM
Bratica JosephPrincipal Financial OfficerAug 03Option Exercise29.601,12533,3008,957Aug 05 08:00 PM
Bratica JosephPrincipal Financial OfficerAug 03Sale155.001,125174,3757,832Aug 05 08:00 PM
Mahatme SandeshEVP, CFO & CBOJul 08Option Exercise19.693,80674,94120,260Jul 09 08:00 PM
Howton David TEVP, General CounselJun 22Option Exercise25.76105,1222,708,440136,993Jun 22 09:17 PM
Howton David TEVP, General CounselJun 22Sale170.88105,12217,962,83131,871Jun 22 09:17 PM
Wigzell Hans Lennart RudolfDirectorMay 20Option Exercise10.085,00050,40018,792May 22 08:00 PM
Wigzell Hans Lennart RudolfDirectorMay 20Sale150.645,000753,21013,792May 22 08:00 PM
Barry RichardDirectorMay 15Sale141.2630,0004,237,9463,159,140May 15 09:02 PM
Wigzell Hans Lennart RudolfDirectorMar 04Option Exercise8.465,00042,30018,792Mar 06 08:01 PM
Wigzell Hans Lennart RudolfDirectorMar 04Sale116.895,000584,45013,792Mar 06 08:01 PM
Mahatme SandeshEVP, CFO & CBODec 13Option Exercise28.88125,0003,610,443155,179Dec 17 08:00 PM
Howton David TEVP, General CounselDec 13Option Exercise21.4878,0001,675,439103,171Dec 17 08:01 PM
Cumbo AlexanderEVP, Chief Commercial OfficerDec 13Option Exercise23.7032,706775,23243,867Dec 17 08:02 PM
Cumbo AlexanderEVP, Chief Commercial OfficerDec 13Sale125.5042,0005,271,0001,867Dec 17 08:02 PM
Howton David TEVP, General CounselDec 13Sale125.5078,0009,789,00025,171Dec 17 08:01 PM
Mahatme SandeshEVP, CFO & CBODec 13Sale125.50125,00015,687,50030,179Dec 17 08:00 PM
Howton David TEVP, General CounselNov 22Option Exercise16.1334,272552,66736,993Nov 26 08:01 PM
Howton David TEVP, General CounselNov 22Sale105.0025,0002,625,00011,993Nov 26 08:01 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.